Pharmacokinetics of Pavaverine After Intraluminal Administration

Observational Study on Papaverine During Cardiac Surgical Procedures

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01436981

Enrollment

Registered

2011-09-20

Start date

2012-10-31

Completion date

2013-01-31

Last updated

2013-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Complications Due to Coronary Artery Bypass Graft, Injury of Internal Mammary Artery

Keywords

papaverine, pharmacokinetic, CABG, Injury of Internal Mammary Artery, Complications Due to Coronary Artery Bypass Graft

Brief summary

The purpose of this study is to determine the pharmacokinetic of papaverine after administration into the artery mammaria interna.

Interventions

PROCEDURECABG

Preparation of artery mammaria interna

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* CABG * Administration of papaverine into mammaria interna

Exclusion criteria

* Allergy against papaverine

Design outcomes

Primary

Measure	Time frame	Description
Maximum plasma concentration of papaverine	4 hours	Serum probes will be analysed for the concentrations of papaverine.

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026